HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.

Journal of Virology
Lifei YangPaul Zhou

Abstract

The development of a successful vaccine against human immunodeficiency virus type 1 (HIV-1) likely requires immunogens that elicit both broadly neutralizing antibodies against envelope spikes and T cell responses that recognize multiple viral proteins. HIV-1 virus-like particles (VLP), because they display authentic envelope spikes on the particle surface, may be developed into such immunogens. However, in one way or the other current systems for HIV-1 VLP production have many limitations. To overcome these, in the present study we developed a novel strategy to produce HIV-1 VLP using stably transfected Drosophila S2 cells. We cotransfected S2 cells with plasmids encoding HIV-1 envelope, Gag, and Rev proteins and a selection marker. After stably transfected S2 clones were established, HIV-1 VLP and their immunogenicity in mice were carefully evaluated. Here, we report that HIV-1 envelope proteins are properly cleaved, glycosylated, and incorporated into VLP with Gag. The amount of VLP released into culture supernatants is comparable to those produced by insect cells infected with recombinant baculoviruses. Moreover, cryo-electron microscopy tomography revealed average 17 spikes per purified VLP, and antigenic epitopes on the sp...Continue Reading

References

Dec 1, 1992·Protein Engineering·C Prodromou, L H Pearl
Jul 14, 1999·Biologicals : Journal of the International Association of Biological Standardization·R H PerssonB Rovinski
Feb 28, 2001·Journal of Immunological Methods·M E SheehyD F Nixon
Jun 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Sayuri SakuragiYuko Morikawa
Jan 18, 2003·Vaccine·Qizhi YaoRichard W Compans
Dec 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Ping ZhuKenneth H Roux
Oct 16, 2004·Reviews in Medical Virology·Linh X DoanQizhi Yao
Dec 14, 2005·Journal of Immunological Methods·V Raúl Gómez-RománMarjorie Robert-Guroff
Oct 22, 2009·The New England Journal of Medicine·Supachai Rerks-NgarmUNKNOWN MOPH-TAVEG Investigators
Oct 7, 2010·Expert Review of Vaccines·António RoldãoPaula M Alves
Oct 30, 2010·Immunity·M Juliana McElrath, Barton F Haynes
Aug 19, 2011·Nature·Laura M WalkerPascal Poignard

❮ Previous
Next ❯

Citations

Jan 9, 2013·Expert Opinion on Biological Therapy·Weizao ChenDimiter S Dimitrov
Oct 28, 2015·Proceedings of the National Academy of Sciences of the United States of America·Pengfei ZhangXiaoyuan Chen
Dec 10, 2015·Expert Review of Vaccines·Anna-Lise Williamson, Edward P Rybicki
Jul 14, 2016·Virologica Sinica·Jinliang LiuFei Deng
Feb 19, 2013·Expert Review of Vaccines·Fabiana FernandesPaula M Alves
Apr 21, 2018·Applied Microbiology and Biotechnology·Monize Caiado DecarliClaudio Alberto Torres Suazo
Aug 3, 2019·Applied Microbiology and Biotechnology·Laura CerveraSònia Gutiérrez-Granados
Jun 30, 2021·Expert Review of Vaccines·Christopher P Karch, Gary R Matyas
Aug 6, 2017·New Biotechnology·J FuenmayorL Cervera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.